Fig. 3

Sequential chemotherapy induced decreased antitumor efficacy of oxaliplatin on saracatinib-resistant HCC. (A) Cell morphology was observed in oxaliplatin and saracatinib-resistant HCC cell lines. (B) oxaliplatin- and saracatinib resistant HCC cell lines exhibited increased IC₅₀ values to oxaliplatin and saracatinib separately. (C) Chemoresistance of oxaliplatin-resistant HCC cell lines to saracatinib was determined with decreased IC₅₀ values compared with wild-type HCC cells. (D) Saracatinib-resistant HCC cell lines exhibited significantly enhanced resistance to oxaliplatin with an increased IC₅₀ to oxaliplatin. (E) Expression of proteins related to proliferation and EMT in oxaliplatin- and saracatinib-resistant cell lines were examined by immunoblotting